ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 277 filers reported holding ROYALTY PHARMA PLC in Q1 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,576,212 | -0.0% | 279,153 | +13.2% | 0.01% | +20.0% |
| Q2 2023 | $7,579,654 | +22.3% | 246,573 | +43.4% | 0.01% | +25.0% |
| Q1 2023 | $6,195,142 | +52.5% | 171,944 | +67.3% | 0.00% | +33.3% |
| Q4 2022 | $4,062,814 | -18.0% | 102,804 | -16.6% | 0.00% | -25.0% |
| Q3 2022 | $4,954,000 | +3.0% | 123,283 | +7.8% | 0.00% | 0.0% |
| Q2 2022 | $4,809,000 | -19.8% | 114,390 | -25.7% | 0.00% | 0.0% |
| Q1 2022 | $5,997,000 | +28.7% | 153,947 | +31.7% | 0.00% | +100.0% |
| Q4 2021 | $4,659,000 | -1.3% | 116,893 | -10.5% | 0.00% | -33.3% |
| Q3 2021 | $4,718,000 | -2.2% | 130,558 | +11.0% | 0.00% | 0.0% |
| Q2 2021 | $4,823,000 | -33.1% | 117,645 | -28.8% | 0.00% | -40.0% |
| Q1 2021 | $7,212,000 | +138.7% | 165,335 | +173.8% | 0.01% | +150.0% |
| Q4 2020 | $3,021,000 | +89.9% | 60,380 | +59.6% | 0.00% | +100.0% |
| Q3 2020 | $1,591,000 | +15810.0% | 37,826 | +18813.0% | 0.00% | – |
| Q2 2020 | $10,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |